The J. David Gladstone Institutes

Agy Therapeutics, Inc.

Li Gan

Lennart Mucke

Thorsten Melcher

Mirella Gonzalez-Zulueta

Erik Roberson

Sarah Mueller-Steiner

Eric M Verdin

Keith McFarland

Daniel J Chin

Richa Wilson

Xu Chen

Min Xie

Shiming Ye

Kristin Anton

The present disclosure provides methods of reducing the level of acetylated Tau in a neuron or a glial cell in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate. The present disclosure provides methods of treating a tauopathy in an individual, the methods involving administering to the individual a prodrug that is converted in the individual to salicylate.

Methods for treating tauopathy

Methods and agents for reducing a level of an acetylated Tau polypeptide in a cell are provided. Methods for treating a tauopathy in an individual are also provided. Also provided is a method for diagnosing a cognitive impairment disorder in an individual. Methods for identifying an agent suitable for treating a tauopathy are also provided.

Methods and compositions for modulating Tau levels

The present invention provides methods for reducing the level of amyloid beta protein in a cell or tissue, the methods generally involving contacting the cell or tissue with an agent that reduces cystatin C levels and/or activity. The present invention provides methods for treating Alzheimer's disease (AD), and methods for treating cerebral angiopathy, in an individual, the methods generally involving administering to an individual having AD a therapeutically effective amount of an agent that reduces cystatin C levels and/or activity. The present invention further provides methods for identifying an agent that reduces cystatin C levels and/or activity.

Methods and compositions for reducing amyloid beta levels

Methods and compositions for modulating tau levels

The present invention provides a method of increasing cathepsin B-induced cleavage of amyloid-&#x3b2; (A&#x3b2;) peptide in a cell or tissue, the method generally involving contacting the cell or tissue with an agent that increases the level of cathepsin B in the cell or tissue. The present invention further provides variant cathepsin B polypeptides that are resistant to inhibition by a cysteine protease inhibitor; as well as nucleic acids encoding the variants, and host cells comprising the nucleic acids.

Method of increasing cathepsin B-induced cleavage of amyloid-&#x3b2; peptides

Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilize RNA interference techniques in the validation process.

High-throughput transcriptome and functional validation analysis

Methods for correlating genes and gene function are provided. Such methods generally involve selecting a candidate gene that appears to be correlated with a particular cellular state or activity and then validating the role of the candidate gene in establishment of such a cellular state or activity. Certain methods utilized RNA interference techniques in the validation process.

Growing community of inventors

Burlingame, CA, United States of America

Li Gan